Gout and Rheumatoid Arthritis NEWEST VERSION
2026 \LATEST UPDATE WITH COMPLETE QUESTIONS
AND CORRECT DETAILED ANSWERS \VERIFIED
100% GRADED A+
xanthine oxidase
chronic gout meds inhibitors
probenecid
pegloticase
first line chronic gout allopurinol
treatment
xanthine oxidase inhibitor; reduces production of uric
allopurinol MOA
acid without disrupting the biosynthesis or vital
purines
acute gout attacks within first 6
allopurinol adverse effects months of treatment delayed
hypersensitivity reactions
bone marrow suppresing
allopurinol dosing 100mg once daily, increase 100mg every 2-4 weeks until uric acid
goal achieved
allopurinol daily max dose 800 mg
allopurinol renal adjusment eGFR <60
allopurinol hypersensitivty presents as SJS, TEN or DRESS
syndrome
increased risk for HLA-B *5801 allele, testing is recommending
allopurinol
hypersensitivty
syndrome
check serum uric acid levels every 2-4 weeks after
monitoring allopurinol
each dose titration, check every 6-12 months after
desired level achieved
feuxostat alternative for patients who can't take allopurinol
, feuxostat contraindications high CV risk, taking azathioprine or mercaptopurine
feuxostat MOA xanthine oxidase inhibitor
feuxostat black box warnings CV death
feuxostat adverse effects acute gout attacks within first 6 months of treatments
feuxostat dosing 40mg once daily, may increase to 80mg is not at goal after 2
weeks
probenecid uricosuric agent
inhibits reabsorption of uric acid at the PCT which
probenecid MOA
promotes urinary excretion of uric acid
pegloticase IV MOA uricase; converts uric acid into allantoin
pegloticase combination with methotrexate
rheumatoid arthritis treatment induce complete remission or minimal disease activity without
goal compromising safety
reduce inflammation and symptoms
rheumatoid arthritis treatment reduce disease activity, preserve function and
goals percent deformity avoid delayed
intervention
NSAIDs and rheumatoid do not slow progression of joint deformitiy
arthritis
rheumatoid arthritis and burst for acute exacerbations
corticosteroids
DMARDs disease modifying anti-rheumatic drugs
methotrexate
sulfasalzine
conventional DMARDs
hydroxychloroqui
ne leflunomide
first line DMARD for RA methotrexate
methotrexate MOA anti-folate, inhibits DNA synthesis, repair and cellular replication
2026 \LATEST UPDATE WITH COMPLETE QUESTIONS
AND CORRECT DETAILED ANSWERS \VERIFIED
100% GRADED A+
xanthine oxidase
chronic gout meds inhibitors
probenecid
pegloticase
first line chronic gout allopurinol
treatment
xanthine oxidase inhibitor; reduces production of uric
allopurinol MOA
acid without disrupting the biosynthesis or vital
purines
acute gout attacks within first 6
allopurinol adverse effects months of treatment delayed
hypersensitivity reactions
bone marrow suppresing
allopurinol dosing 100mg once daily, increase 100mg every 2-4 weeks until uric acid
goal achieved
allopurinol daily max dose 800 mg
allopurinol renal adjusment eGFR <60
allopurinol hypersensitivty presents as SJS, TEN or DRESS
syndrome
increased risk for HLA-B *5801 allele, testing is recommending
allopurinol
hypersensitivty
syndrome
check serum uric acid levels every 2-4 weeks after
monitoring allopurinol
each dose titration, check every 6-12 months after
desired level achieved
feuxostat alternative for patients who can't take allopurinol
, feuxostat contraindications high CV risk, taking azathioprine or mercaptopurine
feuxostat MOA xanthine oxidase inhibitor
feuxostat black box warnings CV death
feuxostat adverse effects acute gout attacks within first 6 months of treatments
feuxostat dosing 40mg once daily, may increase to 80mg is not at goal after 2
weeks
probenecid uricosuric agent
inhibits reabsorption of uric acid at the PCT which
probenecid MOA
promotes urinary excretion of uric acid
pegloticase IV MOA uricase; converts uric acid into allantoin
pegloticase combination with methotrexate
rheumatoid arthritis treatment induce complete remission or minimal disease activity without
goal compromising safety
reduce inflammation and symptoms
rheumatoid arthritis treatment reduce disease activity, preserve function and
goals percent deformity avoid delayed
intervention
NSAIDs and rheumatoid do not slow progression of joint deformitiy
arthritis
rheumatoid arthritis and burst for acute exacerbations
corticosteroids
DMARDs disease modifying anti-rheumatic drugs
methotrexate
sulfasalzine
conventional DMARDs
hydroxychloroqui
ne leflunomide
first line DMARD for RA methotrexate
methotrexate MOA anti-folate, inhibits DNA synthesis, repair and cellular replication
